Introduction

Myeloproliferative Neoplasms (MPNs) are a group of blood cancers associated with rapid and excessive (also known as proliferative) growth of one or more blood cell lineages, caused by mutations of bone marrow stem cells. Although MPNs are defined in simple terms, clinical presentations are far more complex. Patients frequently demonstrate compounding symptoms to resemble those seen in other medical conditions, which complicates diagnosis. Among classic myeloproliferative neoplasms, Essential Thrombocythemia (ET) stands out for its persistent expression of elevated platelet count. This may sound like an insignificant anomaly – yet it often leads to severe side effects such as thrombosis and bleeding, when the condition reaches its advanced stages (e.g., myelofibrosis or acute leukaemia). Genetic testing is critical for determining a definitive diagnosis and distinguishing ET from related disorders, as well as for informing treatment strategies. Our evolving understanding of ET owes much to the transformative role genetic studies have played in the field of haematology. 

Essential thrombocythemia

Essential Thrombocythemia is a bone marrow disorder characterised by the abnormal proliferation of megakaryocytes, with platelet counts exceeding 450 × 10⁹/L. The clinical manifestations of ET are heterogeneous; some individuals present incidentally (meaning the conditions are discovered by chance) from routine blood checks, while others report thrombosis events, including stroke or deep vein thrombosis. Patients with ET often present a unique paradox: despite having an increased platelet count, which typically stops bleeding, presumed platelet dysfunction leads to a tendency to bleed. Common symptoms also include fatigue, headache, and microvascular complications such as paresthesia in the extremities. 

Accurate differential diagnosis is crucial for ET to rule out reactive thrombocytosis, which occurs in the event of infection, inflammation, or iron deficiency. ET also needs to be differentiated from Polycythemia Vera (PV), a condition defined by raised red blood cell counts, and from Primary Myelofibrosis (PMF), which leads to fibrosis of the bone marrow. These diagnoses are of such complexity that molecular testing is required. 

The epidemiology of ET reveals important demographic patterns that influence both diagnosis and management approaches. Studies indicate that ET predominantly affects individuals between 50-70 years of age, with a slight female predominance, particularly in younger patients. The annual incidence ranges from 1-3 cases per 100,000 people in the general population, making it a relatively rare hematologic malignancy. Interestingly, there appears to be geographic variation in incidence rates, with higher reported frequencies in developed countries, potentially due to better diagnostic capabilities and healthcare access rather than true population differences.

Genetic testing in MPNs 

Before the advent of molecular testing, ET diagnosis mostly depended on clinical assessment and bone marrow examinations. Yet these methods often had limitations. The discovery of driver mutations (key genetic changes driving the disease) that activate the JAK-STAT signalling pathway has revolutionised the diagnostic landscape. Such genetic adjustments constitute a molecular ‘signature’ for clonal hematopoiesis, the overproduction of clonal blood cells resulting from a single defective stem cell, not a reactive process. This demonstration of clonality, an expansion of blood cells derived from a single mutant progenitor, is a key criterion in ET diagnosis. Importantly, different mutations are associated with diverse clinical outcomes, highlighting the role of genetic factors in the prediction of clinical outcomes and the direction of therapy.

Defining mutations in essential thrombocythemia

1. JAK2 V617F modification: This oncogenic mutation is found in about 50–60% of ET patients. It causes amino acid replacement of the JAK2 protein, which constitutively activates the JAK-STAT pathway, leading to uncontrolled cell proliferation independent of typical growth signals. In a clinical setting, JAK2-mutated ET can mimic Polycythemia Vera, with an associated rise in haemoglobin and white cell counts, increasing the risk for thrombotic events, especially in long-term therapy 
2. CALR mutations: CALR mutations were identified in 20–30% of ET cases, making them the second most common mutation. The role of CALR is of great interest. It is a multifunctional protein governing calcium homeostasis and protein folding, yet it has not been previously related to hematopoiesis. Even with significantly high platelet counts, CALR mutation patients usually have a lower clinical risk of thrombosis than JAK2 mutation patients. Type 1 CALR mutations have been recognised as a prognostic predictor indicating better treatment outcomes and survival
3. MPL Mutations: MPL mutations in approximately 5% ET patients are present in the thrombopoietin receptor, resulting in abnormal JAK-STAT pathway activation. Although rare, MPL mutations are often associated with intermediate risk status and seen in the myelofibrosis pathway
4. Triple-Negative ET: Between 10 and 15% of the ET population is triple-negative with no identifiable JAK2, CALR, or MPL mutations. This is a diagnostic challenge, as such cases could be early or aberrant (unusual) forms of ET or reactive ET. Recent evidence suggests that there are other, less common mutations in triple-negative ET which can only be detected by sophisticated sequencing technology

Genetics analysis

Molecular diagnostic testing has been recognised as an integral part of the diagnosis of ET in 2022 in the World Health Organisation classification of myeloid neoplasms. Physicians must assess:

Platelet count markedly increased

• Large and persistent megakaryocyte proliferation on bone marrow biopsies
• Features not characteristic of PV, PMF, or other myeloid neoplasms
• Identification of a clonal marker (JAK2, CALR, or MPL mutation)

Genetic testing is especially useful for differentiating between ET and reactive thrombocytosis, which may resemble the disease but lacks clonal mutations. Without molecular identification, doctors often suffer from mistaking them for something else altogether, leading to inappropriate treatment. 

Prognostic significance

As a result of the diagnosis of ET with a specific mutation, it not only allows for the diagnosis but also carries prognostic implications, such as: 

• JAK2-mutated ET: The ET gene presents an increased risk of thrombotic events
• CALR-mutated ET: Indicative of decreased thrombosis risk and overall better prognosis
• MPL-mutated ET: Has intermediate effects, requires close observation
• Triple-negative ET: Shows an equivocal outlook with unpredictable trajectories in the clinical setting. In addition to these driver mutations, other mutations identified through next-generation sequencing, such as ASXL1, TET2, and DNMT3A, have also emerged. These ‘non-driver’ mutations might not have been considered critical for diagnosing ET, but in combination with the essential driver mutations, these mutations can affect disease prognosis and outcomes

Therapeutic implications

ET has traditionally been treated in a way defined by risk stratification, with patients grouped as low or high risk, according to their age, personal history of thrombosis and platelet counts:

Low-risk patients

Most commonly treated with low-dose aspirin. 

High-risk patients

May need cytoreductive therapy (hydroxyurea, interferon). Genetic status adds yet another complication to therapeutic decision-making. 

• JAK2-positive patients: Patients who will most probably be treated with more aggressive antithrombotic therapy 
• Patients positive for CALR may be spared from overtreatment due to their lower risk profile
• Triple negative/MPL positive patients: Care varies from case to case. Emerging therapies such as JAK inhibitors and molecular-targeted drugs can be seen as the next chapter in managing ET. As with every other subject, gaining deep genetic understanding, the field is going in increasingly personalised directions 

Barriers and restraints

Although there have been great breakthroughs, the field of genetic testing for ET still faces several challenges:

Triple-negative patients still struggle with diagnosis. The availability and affordability of molecular testing could vary considerably from one healthcare system to the next, constraining its utility. Genetic data should be considered contextually. The overreliance on molecular data at the expense of clinical and morphological information may lead to misclassification. 

Future directions

The prospective approach for ET management will integrate genetic characterisation. Sequencing techniques such as Next Generation Sequencing (NGS) have great potential to advance the understanding of the clonal topology, mutational risk, and molecular underpinnings in these diseases. Finally, with the growing use of clinical observation and imaging, we can expect to see molecular data as standard clinical data, giving rise to precision personalised medicine in the next 10 years, in which treatment modalities are individualised in relation to the molecular and clinical characteristics of patients. In addition, successful clinical trials assessing novel treatments will expand the treatment horizon beyond symptom control and introduce further disease-modifying therapies.

Summary

Essential Thrombocythemia is characterised by elevated platelet counts and is classified as a chronic myeloproliferative neoplasm. Genetic analysis identifies key driver mutations—JAK2, CALR, and MPL—that form the basis for diagnosis and prognostic evaluation. JAK2 mutations are associated with a higher thrombosis risk, CALR mutations predict favourable outcomes, and MPL mutations indicate intermediate risk. Active research is still ongoing to understand the molecular mechanism and clinical management of triple-negative ET.  Molecular understanding has already served as an integral element of the WHO's criteria. Approaches to therapy today are increasingly based on genetic signatures, with next-generation sequencing and precision therapies as future directions.

FAQs 

Why is genetic testing important in ET?

Ans: Genetic testing confirms the clonality of the disease, differentiates ET from other diseases, and informs prognosis and treatment. 

What are the principal types of mutations found in ET? 

Ans: Major ET mutations are JAK2 V617F (about 50-60%), CALR (20-30%), MPL (about 5%). 

What is triple-negative ET? 

Ans: Triple-negative ET is an ET that tests negative for the mutations JAK2, CALR, and MPL, presenting diagnostic and prognostic challenges. 

Do therapy recommendations vary based on mutation type?

Ans: Yes, treatment may vary according to mutation type; for example, patients who are JAK2 positive are at increased thrombotic risk, while CALR positive patients tend to have a milder disease course.

What does the future hold for ET research?

Ans: As next-generation sequencing advances our molecular definition of ET, this technology might further the development of targeted therapies for personalised medicine.